Fennec Pharmaceuticals Inc. has announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial of PEDMARK® (sodium thiosulfate injection) in Japan. The study enrolled 27 pediatric and adolescent patients with non-metastatic solid tumors and demonstrated a significant reduction in cisplatin-induced hearing loss, with hearing loss rates of 16-24% compared to historically reported rates of 56-63% in patients receiving cisplatin alone. No interference with cisplatin's antitumor activity was observed, as evidenced by an approximate 95% clinical response rate. PEDMARK® was well-tolerated, with no adverse events attributed to the drug. Full study results will be presented at a future scientific meeting and submitted for publication. Fennec plans to pursue registration of PEDMARK® in Japan and is exploring partnering or licensing opportunities in the region.